News coverage about Celyad SA (NASDAQ:CYAD) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celyad SA earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.5793407962691 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of brokerages have recently weighed in on CYAD. ValuEngine upgraded Celyad SA from a “sell” rating to a “hold” rating in a research report on Thursday, June 29th. BidaskClub cut Celyad SA from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $74.00 price target on shares of Celyad SA in a research report on Monday, October 9th.

Shares of Celyad SA (CYAD) traded down 0.29% during mid-day trading on Tuesday, hitting $59.79. The stock had a trading volume of 3,948 shares. The stock’s market cap is $569.50 million. Celyad SA has a one year low of $16.31 and a one year high of $64.75. The firm has a 50 day moving average of $57.68 and a 200 day moving average of $57.68.

ILLEGAL ACTIVITY WARNING: “Celyad SA (CYAD) Getting Somewhat Favorable Media Coverage, Accern Reports” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Insider Buying and Selling by Quarter for Celyad SA (NASDAQ:CYAD)

Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.